Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Weichhart T et al. – The results place mTOR in a novel immunoregulatory context that highlights the potential of mTOR inhibitors as both immunosuppressant and anti–cancer agents.

Related Articles

Targeting the mTOR Pathway in Neuroendocrine Tumors
Clinical Journal of Oncology Nursing, 10/07/09    Relevance Score: 91%

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
Journal of Hematology & Oncology, 10/30/09    Relevance Score: 90%

Chondrocyte autophagy is stimulated by HIF-1 dependent AMPK activation and mTOR suppression
Pediatric Nephrology, 11/04/09    Relevance Score: 87%

The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Journal of the American Society of Nephrology, 11/04/09    Relevance Score: 87%

Differential Healing After Sirolimus, Paclitaxel, and Bare Metal Stent Placement in Combination With Peroxisome Proliferator-Activator Receptor gamma Agonists. Requirement for mTOR/Akt2 in PPAR-gamma Activation
Circulation Research, 10/02/09    Relevance Score: 84%

Today in Hematology/Oncology...keeping you current

Effects of biological drug adalimumab on tumour necrosis factor-alpha-converting enzyme activation
Immunology & Cell Biology, 12/08/09

The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/07/09

Small-for-size liver graft injury--impact on tumor behavior
Transplantation Reviews, 12/07/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address